Hyperthermic Intraperitoneal Chemoperfusion (HIPEC) in Gastric Cancer (ProPeC)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04180761|
Recruitment Status : Recruiting
First Posted : November 29, 2019
Last Update Posted : November 29, 2019
|Condition or disease||Intervention/treatment||Phase|
|Gastric Neoplasms||Drug: intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)||Phase 2|
An operation and the constant further development of the surgical techniques can not always prevent the recurrence of a tumor of the stomach or the transition from the esophagus to the stomach. As reason for this recurrence, the investigators assume that the tumor was already present at the time of the surgery and has crossed the boundaries of the stomach or free tumor cells are located in the peritoneal cavity, even if they can't be found with the bare eye or imaging methods. Such free tumor cells have the possibility of developing metastases within the abdominal cavity.
An innovative local treatment method is being tested in Tübingen and applied to remove any remaining free tumor cells or very small and invisible residual tumors. These free tumor cells can be determined prior to the start of treatment by peritoneal endoscopy (diagnostic laparoscopy). If these can be identified by lavage of the abdominal cavity there is an increased risk for the development of peritoneal metastases. Therefore, in patients with detected free tumor cells in the lavage water of the abdominal cavity, after the removal of the stomach, should be used once a chemotherapy in the abdominal cavity, which is warmer than the body (intraoperative hyperthermic chemotherapy, HIPEC). In this study the investigators want to demonstrate, that the single administration of intraoperative HIPEC with cisplatin and doxorubicin in addition to routine surgery delays the onset of peritoneal metastases and the additional therapy with its low risks is reasonable.
|Study Type :||Interventional (Clinical Trial)|
|Estimated Enrollment :||46 participants|
|Intervention Model:||Single Group Assignment|
|Masking:||None (Open Label)|
|Official Title:||Phase II Pilot Study to Reduce the Incidence of Peritoneal Carcinoma After Curative Gastrectomy of Gastric Carcinoma or Adenocarcinoma of Gastroesophageal Transition by Hyperthermic Intraperitoneal Chemoperfusion|
|Estimated Study Start Date :||November 2019|
|Estimated Primary Completion Date :||March 2022|
|Estimated Study Completion Date :||September 2022|
Doxorubicin (15 mg/m²/body surface) Cisplatin (75 mg/m²/body surface) applied as hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy.
All drugs used are approved.
Drug: intraoperative hyperthermic intraperitoneal chemotherapy (HIPEC)
single dose application of hyperthermic intraperitoneal chemotherapy (HIPEC) at 42.5°C for 60 minutes after the gastrectomy
- Incidence of peritoneal metastases and proportion of patients free from peritoneal metastasis after one year after HIPEC. [ Time Frame: one year ]The primary objective of the study is to estimate the effect of a combined therapy with gastrectomy and HIPEC in localized advanced gastric cancer. The primary target is the incidence of peritoneal metastases in CT and the proportion of patients who after one year are free from peritoneal metastasis. The study is intended to provide planning data for a subsequent Phase III study in the form of an RCT.
- Overall Survival (OS) [ Time Frame: one year ]Overall Survival (OS) measured in years.
- Progression-free survival (PFS) [ Time Frame: one year ]Progression-free survival (PFS) based on imaging (CT).
- Number of participants with treatment-related adverse events as assessed by grading according to CTCAE v5.0 and Clavien-Dindo. [ Time Frame: one year ]
Expected adverse events (AEs) of particular interest must be recorded from grade ≥ III according to CTCAE v5.0 or postoperative complications according to Clavien-Dindo classification from grade ≥ 3b by AE/ADR reporting.
Unexpected and expected AEs must be documented and reported as SAE from grade IV according to CTCAE v5.0 or from grade 4-5 according to Clavien-Dindo classification.
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04180761
|Contact: Alfred Königsrainer, MD||+49-7071-29- ext firstname.lastname@example.org|
|University Department of General, Visceral and Transplant Surgery||Recruiting|
|Tuebingen, BW, Germany, 72076|
|Contact: Alfred Königsrainer, MD +49-7071-29 ext -86620 email@example.com|
|Principal Investigator: Alfred Königsrainer, MD|
|Sub-Investigator: Can Yurttas, MD|